Boehringer Ingelheim
News/ News/ Sales and Marketing
Boehringer, Takeda make it into global top 15 employer list
Phil Taylor
Boehringer Ingelheim, employ, human resources, Takeda
0 Comment
Digital/ News/ News/ News/ R&D
BI, Click Therapeutics expand collaboration to PDT for schizophrenia
Nicole Raleigh
Boehringer Ingelheim, Click Therapeutics, collaboration, digital therapeutics, mental health, PDT, schizophrenia
0 Comment
Market Access/ News/ News/ News/ Patients
NICE backs use of Boehringer’s Ofev in IPF from diagnosis
Phil Taylor
Boehringer Ingelheim, Esbriet, HEOR, idiopathic pulmonary fibrosis, NHS, NICE, Ofev, Roche
0 Comment
Appointments/ News/ Sales and Marketing
Changing Faces: biopharma hires from November 2022
Jonah Comstock
Acelyrin, ADC Therapeutics, Almirall, Amarin Pharmaceuticals, Amy Levin, Angelini Pharma, AstraZeneca, Atriva Therapeutics, Barbara Sanders, biopharma hires, Boehringer Ingelheim, C-Suite, Carlos Gallardo, Christian Pangratz, Elena Ritsou, Imophoron, Incyte Biosciences, Jacopo Andreose, James McCarthy, Jérôme Marzinski, Kristen Harrington-Smith, Luke Devey, Lykke Hinsch Gylvin, Mainz Biomed, Mardi C. Dier, Mercedes Diaz, Mina Kim, Nivedita Valentine, Novacyt, Oxsonics Therapeutics, Peter Graham, Peter Williams, pharma hires, Pharmanovia, Quell Therapeutics, Richard Bungay, Richard Pallin, Sander van Deventer, Scott Curley, Sheena Powell, SpectrumX, Stefan Woxström, VectorY, Virax Biolabs
0 Comment
News/ News/ Sales and Marketing
US court throws out lawsuits alleging Zantac caused cancer
Phil Taylor
Boehringer Ingelheim, GlaxoSmithKline, Haleon, Johnson & Johnson, litigation, Pfizer, safety, Zantac
0 Comment
Boehringer recruits former Novartis’ neurosciences head as its CMO
Phil Taylor
appointment, Boehringer Ingelheim, R&D, senior management
0 Comment
Digital/ News/ News/ News/ R&D
Boehringer taps Medidata e-clinical tech for another five years
Phil Taylor
Boehringer Ingelheim, clinical trials, decentralised clinical trials, electronic data capture, Medidata
0 Comment
Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3
Phil Taylor
Boehringer Ingelheim, interstitial lung diseases, Ofev, respiratory
0 Comment